Journal of Neural Transmission

, Volume 116, Issue 2, pp 203–212

Combined CSF tau, p-tau181 and amyloid-β 38/40/42 for diagnosing Alzheimer’s disease

  • Volker Welge
  • Oliver Fiege
  • Piotr Lewczuk
  • Brit Mollenhauer
  • Hermann Esselmann
  • Hans-Wolfgang Klafki
  • Stefanie Wolf
  • Claudia Trenkwalder
  • Markus Otto
  • Johannes Kornhuber
  • Jens Wiltfang
  • Mirko Bibl
Alzheimer's Disease and Related Disorders - Original Article

DOI: 10.1007/s00702-008-0177-6

Cite this article as:
Welge, V., Fiege, O., Lewczuk, P. et al. J Neural Transm (2009) 116: 203. doi:10.1007/s00702-008-0177-6
  • 516 Downloads

Abstract

Cerebrospinal fluid (CSF) concentrations of amyloid-β (Aβ) 1-38, 1-40, 1-42, total-tau and phospho-tau in samples from 156 patients with Alzheimer’s disease (AD) (n = 44), depressive cognitive complainers (DCC, n = 25) and various other forms of non-Alzheimer dementias (NAD, n = 87) were analyzed by electrochemiluminescence and enzyme linked immunosorbent assay, respectively. A significant decrease of CSF Aβ1-42 was the most powerful single marker for differentiation of AD from DCC, yielding accuracies of beyond 85%. Increased p-tau and the ratio Aβ1-42/Aβ1-38 yielded accuracies of beyond 80 and 85%, respectively, to discriminate AD versus NAD. Combining p-tau with Aβ1-42/Aβ1-38 resulted in a sensitivity of 94% for detection of AD and 85% specificity for excluding NAD. Decreased CSF Aβ1-42 represents a core biomarker for AD. The lack of specificity for exclusion of NAD can be most effectively compensated by the ratio Aβ1-42/Aβ1-38. The ratio Aβ1-42/Aβ1-38/p-tau powerfully discriminates AD versus NAD and fulfils the accuracy requirements for an applicable screening and differential diagnostic AD biomarker.

Keywords

Alzheimer’s disease Cerebrospinal fluid Amyloid-β peptides Biomarkers ELISA Electrochemiluminescence 

Abbreviations

Aβ peptides

Amyloid-beta peptides

Aβ-SDS-PAGE/immunoblot

Amyloid-beta-sodium-dodecyl-sulphate-polyacrylamide-gel electrophoresis with western immunoblot

AD

Alzheimer’s disease

CSF

Cerebrospinal fluid

DCC

Depressive cognitive complainers

ELISA

Enzyme linked immunosorbent assay

MMSE

Mini-mental-status examination

NINCDS-ADRDA

National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer’s Disease and Related Disorders Association

NINDS-SPSP

National Institute of Neurological Disorders and Stroke and the Society for PSP

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Volker Welge
    • 1
  • Oliver Fiege
    • 1
  • Piotr Lewczuk
    • 2
  • Brit Mollenhauer
    • 3
  • Hermann Esselmann
    • 2
  • Hans-Wolfgang Klafki
    • 1
  • Stefanie Wolf
    • 3
  • Claudia Trenkwalder
    • 4
  • Markus Otto
    • 5
  • Johannes Kornhuber
    • 2
  • Jens Wiltfang
    • 1
  • Mirko Bibl
    • 1
  1. 1.Klinik für Psychiatrie und PsychotherapieUniversität Duisburg-EssenEssenGermany
  2. 2.Department of Psychiatry and PsychotherapyUniversity of Erlangen-NurembergErlangenGermany
  3. 3.Department of PsychiatryUniversity of GoettingenGöttingenGermany
  4. 4.University of GoettingenKasselGermany
  5. 5.Department of NeurologyUniversity of UlmUlmGermany

Personalised recommendations